Open AccessAnti-Endotoxin Therapy in Primate Bacteremia with HA-1A and BPI
Author(s) -
Michael A. Rogy,
Lyle L. Moldawer,
Hester S. A. Oldenburg,
W. A. Thompson,
Walton J. Montegut,
Sarah A. Stackpole,
Ashwini Kumar,
Michael A. Palladino,
Marian N. Marra,
Stephen F. Lowry
Publication year - 1994
Publication title -
annals of surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.153
H-Index - 309
eISSN - 1528-1140
pISSN - 0003-4932
DOI - 10.1097/00000658-199407000-00011
Subject(s) - medicine , bacteremia , in vivo , lipopolysaccharide , antibody , neutralizing antibody , immunology , pharmacology , microbiology and biotechnology , biology , antibiotics
The in vivo neutralizing activities of an anti-lipopolysaccharide (LPS) antibody HA-1A (Centoxin [Centocor, Malvern, PA]), a human immunoglobulin M monoclonal antibody, and of bactericidal/permeability-increasing protein (BPI), an endogenously produced human LPS-neutralizing protein, were studied in a primate model of lethal Escherichia coli bacteremia.